Cullinan Oncology stock target raised to $33 at H.C. Wainwright
H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.
Hosted on MSN16h
20 Target Beauty Products That Have No Right To Work So Well For Such A Low Price
Open for beauty products that cost less and last waaaaay longer than your specialty coffee order. View Entire Post › ...
Neurology Advisor2d
Oral SIGMAR1 Targeting Agent Looks Promising in Early Alzheimer Disease Trial
Topline data were published from a phase 2b/3 study evaluating blarcamesine for the treatment of early Alzheimer disease.
ClearPoint Neuro price target raised to $20 from $15 at B. Riley
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating on the shares.
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...